2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Predicting response to bacillus Calmette-Guerin (BCG) - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Ashish M. Kamat presented data his group has been accumulating in an effort to predict response to BCG in patients with non-muscle invasive bladder cancer (NMIBC). He pointed out that BCG is a therapy that has been around for 40+ years, and, although it isn’t perfect, we have not found anything better yet. About 30% of patients will fail, and non-responders tend to progress prior to curative cystectomy, increasing cancer-specific mortality.

auaHe highlighted the fact that it is an immunologic agent, and that its efficacy is completely based on the dosage…weekly doses for 6 weeks with maintenance courses is the optimal dosing schedule. Other dosing schedules are suboptimal and correlate to weaker immune cytokine responses. Because of this finding, his group has evaluated cytokines comprehensively using a panel, as well as tissue-, urine-, and blood-based markers in patients treated with BCG. Induced IL8 levels (among other cytokines) at the 6th instillation were highest in the responders.

By combining multiple cytokine levels into a nomogram, they were able to stratify responders and non-responders with a 90% accuracy. He highlighted a 2012 trial showing that intradermal BCG may increase the response but also showed a trial from almost 20 years ago showing that intradermal BCG did not have an increased response as well as a recent report demonstrating that different strains may actually have better responses. The Connaught strain had a more durable response rate than did Tice BCG.

AUA/NCI Specialized Programs of Research Excellence (SPORE) Joint Workshop

Presented by Ashish M. Kamat, MD at the American Urological Association (AUA) Annual Meeting- May 16 - 21, 2014 - Orlando, Florida USA

MD Anderson Cancer Center, Houston, TX USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe